Haleon plc (LON:HLN) Given Consensus Recommendation of “Hold” by Analysts

Haleon plc (LON:HLN) has earned a consensus rating of “Hold” from the five research firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is GBX 387.80.

Several research firms have issued reports on HLN. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Haleon from GBX 335 to GBX 320 and set a “sell” rating on the stock in a research report on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 400 price objective on shares of Haleon in a research note on Friday, July 31st. JPMorgan Chase & Co. lowered their price objective on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Royal Bank Of Canada boosted their target price on shares of Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research note on Tuesday, August 11th. Finally, Berenberg Bank increased their target price on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a report on Wednesday, August 5th.

Haleon Trading Down 0.3%

Shares of LON:HLN opened at GBX 335.24 on Friday. Haleon has a fifty-two week low of GBX 317.80 and a fifty-two week high of GBX 416.10. The company has a quick ratio of 0.93, a current ratio of 0.69 and a debt-to-equity ratio of 50.38. The company has a market cap of £29.49 billion, a PE ratio of 18.52, a P/E/G ratio of 1.49 and a beta of 0.24. The company’s 50-day moving average price is GBX 362.67 and its 200 day moving average price is GBX 357.62.

Haleon (LON:HLN) last issued its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. Sell-side analysts anticipate that Haleon will post 19.5033282 earnings per share for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.